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Abstract
Background—To establish whether Parkinson’s disease (PD) brains previously described to 
have decreased glucocerebrosidase activity exhibit accumulation of the lysosomal enzyme’s 
substrate, glucosylceramide, or other changes in lipid composition.
Methods—Lipidomic analyses and cholesterol measurements were performed on the putamen (n 
= 5-7) and cerebellum (n = 7-14) of controls, Parkinson’s disease brains with heterozygote GBA1 
mutations (PD+GBA), or sporadic PD.
Results—Total glucosylceramide levels were unchanged in both PD+GBA and sporadic PD 
brains when compared with controls. No changes in glucosylsphingosine (deacetylated 
glucosylceramide), sphingomyelin, gangliosides (GM2, GM3), or total cholesterol were observed 
in either putamen or cerebellum.
Conclusions—This study did not demonstrate glucocerebrosidase substrate accumulation in PD 
brains with heterozygote GBA1 mutations in areas of the brain with low α-synuclein pathology.
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Mutations in the GBA1 gene are numerically the most important genetic risk factor for 
developing Parkinson’s disease (PD).1,2 A large multicenter study showed that PD patients 
had an odds ratio of over 5 for carrying a GBA1 mutation, compared with a similar-sized 
control population.1 GBA1 encodes for the lysosomal enzyme glucocerebrosidase (GCase), 
which catabolizes the sphingolipid glucosylceramide (GlcCer) to glucose and ceramide. 
Homozygous GBA1 mutations result in the accumulation of GlcCer in lysosomes and cause 
the lysosomal storage disorder Gaucher disease (GD).3
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The activity of GCase is decreased in PD brains with heterozygous GBA1 mutations (PD
+GBA), with the greatest decrease (58%) in the substantia nigra,4 the area of the brain with 
the greatest PD pathology. Notably, GCase was also significantly decreased by 33% in the 
substantia nigra of sporadic PD brains.4 GCase activity also has been reported to be 
decreased in the anterior cingulate cortex of sporadic PD brains.5
Defects in the autophagy–lysosomal pathway (ALP) are implicated in the accumulation/
aggregation of α-synuclein and mitochondrial dysfunction observed in PD.6-8 Cellular and 
animal models of GCase deficiency have shown impaired ALP, resulting in increased 
asynuclein levels and decreased mitochondrial function in neurons and brain.9-13 The 
mechanism by which loss of GCase activity affects the ALP is unclear. The accumulation of 
GlcCer or glucosylsphingosine (GlcSph; deacetylated GlcCer) could contribute to lysosomal 
dysfunction and toxicity, and so to the pathogenesis of PD in GBA1 mutation carriers.13,14 
However, although PD+GBA brains have significant loss of GCase activity, the residual 
function of the enzyme may be sufficient to prevent substrate accumulation. Given the role 
of GCase in sphingolipid metabolism, we have performed lipidomic analysis of GlcCer, 
GlcSph, sphingomyelin, and gangliosides in the putamen and cerebellum of PD+GBA brains 
that we have previously reported to have decreased GCase activity.4
Materials and Methods
Postmortem Brain Material
Postmortem control brains, PD brains with known heterozygote GBA1 mutations (PD
+GBA), and sporadic PD brains were obtained from the Queen Square Brain Bank for 
Neurological Disorders after local ethical approval. GBA1 mutations were identified by 
Sanger sequencing all 11 exons of the open reading frame. All donors gave written informed 
consent. All PD cases met the UK Brain Bank Clinical Criteria for Parkinson’s disease. The 
pathological and biochemical analyses of these brains have been described.2,4 Lipidomic 
analyses were performed on the putamen (n = 5-7 per group) and cerebellum (n = 7-14 per 
group). The genotypes of the PD+GBA putamen samples were one L444P/wt, one 
R463C/wt, one R193E/wt, and two N370S/wt. The genotypes of the PD+GBA cerebellum 
samples were five L444P/wt, one R463C/wt, one R131C/wt, three N370S/wt, one 
RecA456P/wt, one D409H/wt, one G193E/wt, and one RecNciI/wt. The mean age (years ± 
standard error of the mean) for each cohort was: control, 65.4 ± 6.3; PD+GBA, 67.8 ± 3.0; 
sporadic PD, 69.6 ± 2.9. The postmortem delay (hours ± standard error of the mean) of each 
cohort: control, 55.1 ± 8.5; PD+GBA, 50.5 ± 6.6; sporadic PD, 37.8 ± 3.3.
Total Cholesterol Measurement
Brain tissue was homogenized in isolation medium (250 mM sucrose, 10 mM Tris, pH 7.4, 1 
mM ethylenediaminetetra-aetic acid) and total cholesterol (free cholesterol and cholesteryl 
esters) measured using the Amplex Red Cholesterol Assay Kit (Life Technologies, Paisley, 
UK). Total cholesterol concentration (μg/mL) was normalized against the protein 
concentration of each sample (Pierce BCA Protein Assay Kit, Life Technologies, Paisley, 
UK).
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Quantitative analysis of sphingolipids was performed by using liquid chromatography and 
tandem mass spectrometry. Briefly, tissues were homogenized in water to give a final 
concentration of approximately 100 mg/mL (w/v). The homogenate was extracted with 1 
mL of a solution of acetonitrile:methanol:water (97:2:1, v/v/v) at room temperature. Extracts 
were injected onto an Atlantis HILIC silica column (Waters Corp, Milford, MA) for 
separation of GlcCer and GalCer, and these molecules were detected by using multiple 
reaction monitoring (MRM) mode tandem mass spectrometry with an AB Sciex API-5000 
mass spectrometer (AB Sciex, Framingham, MA). For other lipid analysis, extracts were 
injected onto an Acquity BEH C8 column (Waters Corp., Milford, MA), and MRM mode 
detection was performed using an AB Sciex API-5000 mass spectrometer. For GlcSph 
analysis, homogenate was extracted with 1 mL of acetonitrile:methanol:water (48.5:50.5:1, 
v/v/v), and extracts were injected onto an Acquity BEH HILIC column to resolve GlcSph 
from psychosine, (Waters Corp., Milford, MA) and detected using MRM mode with an 
Agilent 6490 mass spectrometer. Except for phosphatidylcholine, all analytes were 
quantitated against standards obtained from Matreya, LLC (Pleasant Gap, PA).
Results
Lipidomic analyses were performed on the putamen and the cerebellum. The substantia 
nigra was not measured because of insufficient material. In a previous biochemical study, 
the activity of GCase has been reported to be significantly decreased (P < 0.01 vs. control) 
by 48% in the putamen of PD+GBA brains and 47% in the cerebellum.4 In sporadic PD, 
GCase activity was decreased by 19% (nonsignificant) and 24% (P < 0.05 vs. control) in the 
putamen and cerebellum, respectively.4
Total GlcCer levels in the putamen and cerebellum were similar in control, PD+GBA, and 
sporadic PD brains when normalized against protein (Table 1). No changes were observed 
when total GlcCer levels were normalized to sphingomyelin in putamen or cerebellum (data 
not shown). Plotting total GlcCer levels against GCase activity for each individual did not 
show any correlation either (Fig. 1). Similar to previous studies, the predominant GlcCer 
species in human brain was C18:0.15,16 The GlcCer C24:0 species was significantly 
increased in PD+GBA cerebellum by 212% (P < 0.05), when compared with control. No 
other changes in GlcCer species were observed in PD+GBA or sporadic PD brains.
The levels of GlcSph have been shown to be increased in human GD brains and GD mouse 
models.10,14,15,17 GlcSph was unaffected in the putamen and cerebellum of PD+GBA and 
sporadic PD brains, when compared with control.
No changes were seen in the amounts of lactosylceramide or sphingomyelin in either the 
putamen or cerebellum of PD+GBA or sporadic PD brains (Table 1). Although not 
significant, a trend was seen for increased ganglioside levels (GM2 and GM3) in the 
putamen of PD+GBA brains.
The levels of cholesterol were not significantly affected in the putamen (control, 375 ± 35 
nmol/mg protein; PD+GBA, 328 ± 17; sporadic PD, 316 ± 22). The amount of 
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phosphatidylcholine in the putamen was also unaffected (control, 20.93 ± 5.39 AU/mg of 
protein; PD+GBA, 23.49 ± 1.23 AU/mg of protein; sporadic PD, 25.36 ± 0.59 AU/mg of 
protein).
Discussion
In this study, we found no evidence of accumulation of either GlcCer or GlcSph in the 
putamen or cerebellum of PD brains with heterozygote GBA1 mutations. No changes were 
observed in sphingomyelin or cholesterol, although a trend was seen for increased GM2 and 
GM3 gangliosides in the putamen of PD+GBA brains. Possibly GlcCer accumulation is 
masked by shunting to these upstream gangliosides and other lipid species not analyzed in 
this study. We did not investigate ceramide, but both a strong trend for5 and a statistically 
significant18 decrease in total ceramide levels have been reported in sporadic PD anterior 
cingulate cortex,5 suggesting that changes in sphingolipid metabolism may occur in PD. 
Analysis of sphingolipids in regions of the limbic system with significant asynuclein 
pathology would be an interesting future study.
GCase activity was decreased by approximately 50% in the putamen and cerebellum of PD
+GBA brains, with both regions showing a significant decrease in GCase protein 
expression.4 Heterozygous GBA1 KO mice with a similar GCase deficiency do not show an 
increase in GlcCer or GlcSph in brain up to 6 months of age.10 Because the lipidomic 
analyses were performed on brain lysates, conceivably substrate accumulation in neurons is 
being masked by the more numerous glia. Subcellular fractionation also may indicate 
localized increases in GlcCer. Indeed, small increases in GlcCer have been reported in 
primary cultured cortical neurons with GCase knockdown (approximately 50% GCase 
activity loss)9 or dopaminergic neurons differentiated from inducible pluripotent stem cells 
harboring heterozygote GBA1 mutations.13 However, in both cases, substrate accumulation 
was much less than the degree reported in type II/III GD brains.15
The mechanism by which GCase deficiency increases risk for developing PD is still unclear. 
In vitro experiments have suggested that GlcCer can stabilize soluble oligomeric forms of 
recombinant α-synuclein at lysosomal pH.9 Although potentially relevant to GD patients 
who develop PD, this may not be the mechanism for PD+GBA patients lacking substrate 
accumulation in the brain. The GCase variant E326K has recently been reported to be the 
most common GBA1 mutation in a British cohort of early-onset PD cases (≤50 y of age).19 
Although this mutation on its own decreases GCase activity, residual activity is still much 
greater than other GD mutations such as N370S and L444P.20-23 Although still unproven, 
heterozygote E326K mutations causing GlcCer accumulation seems unlikely.
Because GCase is involved in sphingolipid metabolism, possibly changes in the composition 
of cellular membranes will contribute to PD. Impairment of the ALP has been suggested to 
contribute to the increased α-synuclein observed in cellular and animal models of GCase 
deficiency.9,11,13 Membrane dynamics are critical for macroautophagy, ranging from 
biogenesis of the phagophore to the fusion of autophagosomes (APs) with lysosomes.24 
Changes in the lipid content or cholesterol can impair the fusion of APs with lysosomes.25 
Increased lysosomal cholesterol content or changes in the lipid composition also 
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significantly inhibits chaperone-mediated autophagy.26,27 Therefore, although we or others 
have not found total changes in sphingolipid or cholesterol content in PD brains with GBA1 
mutations, sporadic PD brains, or GD brains,5,15,28 possibly the subcellular composition of 
organelles, lipid rafts, and other functional membrane domains are affected. Magnetic 
resonance spectroscopic imaging of PD patients with GBA1 mutations has suggested that 
phospholipid metabolism is affected.29
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Plot of GCase activity against GlcCer levels for control, PD+GBA, and PD samples in 
putamen (A) and cerebellum (B). Relationship between GCase activity4 and GlcCer for each 
heterozygote GBA mutation is shown in the right panel. [Color figure can be viewed in the 
online issue, which is available at wileyonlinelibrary.com.]
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Table 1
Sphingolipid and ganglioside levels unchanged in PD+GBA brains
Putamen Cerebellum
Lipid Control (n = 5) PD+GBA (n = 5) PD (n = 7) Control (n = 7) PD+GBA (n = 14) PD (n = 13)
Total GlcCer 7.66 ± 1.23 5.25 ± 0.78 5.56 ± 0.99 3.38 ± 0.32 4.16 ± 0.48 2.94 ± 0.40
GlcCer C16:0 0.42 ± 0.10 0.31 ± 0.11 0.15 ± 0.03 0.29 ± 0.05 0.29 ± 0.04 0.19 ± 0.04
GlcCer C18:0 4.31 ± 0.88 2.73 ± 0.55 2.48 ± 0.11 2.08 ± 0.17 2.35 ± 0.33 1.57 ± 0.23
GlcCer C20:0 0.30 ± 0.08 0.19 ± 0.08 0.14 ± 0.03 0.18 ± 0.03 0.16 ± 0.03 0.15 ± 0.03
GlcCer C22:0 0.12 ± 0.03 0.16 ± 0.05 0.08 ± 0.05 0.01 ± 0.01 0.03 ± 0.01 0.00 ± 0.00
GlcCer C23:0 0.25 ± 0.03 0.16 ± 0.03 0.26 ± 0.08 0.05 ± 0.02 0.10 ± 0.02 0.07 ± 0.01
GlcCer C24:1 1.62 ± 0.21 1.21 ± 0.38 1.83 ± 0.65 0.61 ± 0.10 0.88 ± 0.15 0.74 ± 0.12
GlcCer C24:0 0.64 ± 0.06 0.49 ± 0.07 0.63 ± 0.22 0.17 ± 0.04 0.36 ± 0.04* 0.21 ± 0.04
GlcSph 0.14 ± 0.07 0.17 ± 0.08 0.35 ± 0.15 0.27 ± 0.06 0.20 ± 0.06 0.23 ± 0.06
LacCer 172 ± 53 203 ± 37 283 ± 81 219 ± 16 222 ± 22 213 ± 13
GM2 C18:0 386 ± 122 530 ± 53 498 ± 39 468 ± 30 468 ± 33 504 ± 45
GM3 C18:0 95 ± 41 135 ± 26 108 ± 24 90 ± 9 76 ± 10 103 ± 14
Sphingomyelin 26.4 ± 7.0 29.9 ± 2.0 31.6 ± 0.9 34.6 ± 1.2 36.7 ± 1.4 38.4 ± 2.6
Total glucosylceramide (GlcCer) and the different GlcCer species (C16:0, C18:0, C20:0, C22:0, C23:0, C24:0, C24:1, C24:0), glucosylspingosine 
(GlcSph) lactosylceramide (LacCer), GM2, GM3, and sphingomyelin were analyzed by LC-MS/MS. Units are ng lipid/mg protein, except GM2/
GM3, μg/mg protein; sphingomyelin, mg/mg protein. Data are mean ± SEM.
*
P < 0.05 vs. control as determined by one-way analysis of variance followed by Tukey HSD test.
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